Acquired in-process research and developed expense.

No definition available.

Name:	nmra_AcquiredInProcessResearchAndDevelopedExpense
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Acquired in-process research and development

+ References

No definition available.

+ Details

Name:	nmra_AcquiredInProcessResearchAndDevelopment
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Acquisition date fair value of shares transferred

+ References

No definition available.

+ Details

Name:	nmra_AcquisitionDateFairValueOfSharesTransferred
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent consideration, milestone payment.

+ References

No definition available.

+ Details

Name:	nmra_ContingentConsiderationMilestonePayment
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent consideration, milestone payment settled in cash

+ References

No definition available.

+ Details

Name:	nmra_ContingentConsiderationMilestonePaymentSettledInCash
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment due description.

+ References

No definition available.

+ Details

Name:	nmra_MilestonePaymentDueDescription
Namespace Prefix:	nmra_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of license agreements.

+ References

No definition available.

+ Details

Name:	nmra_NumberOfLicenseAgreements
Namespace Prefix:	nmra_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of milestone achieved.

+ References

No definition available.

+ Details

Name:	nmra_NumberOfMilestoneAchieved
Namespace Prefix:	nmra_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Shares issued based on volume weighted average price per share prior to date milestone was met.

+ References

No definition available.

+ Details

Name:	nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet
Namespace Prefix:	nmra_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	nmra_UpfrontCashPayment
Namespace Prefix:	nmra_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront consideration transferred shares.

+ References

No definition available.

+ Details

Name:	nmra_UpfrontConsiderationTransferredShares
Namespace Prefix:	nmra_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.

+ References

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_AssetAcquisitionAxis=nmra_AmgenIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=nmra_VanderbiltIprDAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=nmra_BlackthornTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=nmra_NavacaprantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentAndRegulatoryApprovalMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=nmra_SalesBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=nmra_Nmra511Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_BlackthornCarveoutPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_SyllableMergerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=nmra_SyllableLifeSciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_AlairionMergerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=nmra_AlairionIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedCommercializationEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedDevelopmentEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=nmra_SeriesA2ConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nmra_CaseOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=nmra_CommercialMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nmra_CaseTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions of Assets - Additional Information (Details)	1 Months Ended							3 Months Ended		12 Months Ended
	Dec. 31, 2023 USD ($) shares	Nov. 30, 2023 USD ($)	Feb. 28, 2022 USD ($)	Sep. 30, 2021 USD ($) Agreements shares	Nov. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2024 USD ($) Milestones	Dec. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Amgen Inc.
Business Acquisition [Line Items]
Number of license agreements \| Agreements				2
Vanderbilt IPR&D Assets
Business Acquisition [Line Items]
Contingent consideration deemed due or payable								$ 0
BlackThorn Merger Agreement
Business Acquisition [Line Items]
Contingent consideration, milestone payment settled in cash							$ 10,000,000
Number of milestone achieved \| Milestones								0
BlackThorn Merger Agreement \| BlackThorn Therapeutics, Inc.
Business Acquisition [Line Items]
Contingent consideration deemed due or payable								$ 0
Contingent consideration payable in cash	$ 2,300,000
Acquired in-process research and developed expense									$ 60,800,000
BlackThorn Merger Agreement \| BlackThorn Therapeutics, Inc. \| Common Stock
Business Acquisition [Line Items]
Shares issued based on volume weighted average price per share prior to date milestone was met \| shares	6,072,445
BlackThorn Merger Agreement \| navacaprant
Business Acquisition [Line Items]
Milestone payment due description								milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,
BlackThorn Merger Agreement \| navacaprant \| Maximum \| Development and Regulatory Approval Milestones
Business Acquisition [Line Items]
Contingent consideration							365,000,000
BlackThorn Merger Agreement \| navacaprant \| Maximum \| Sales-based Milestones
Business Acquisition [Line Items]
Contingent consideration							450,000,000
BlackThorn Merger Agreement \| NMRA-511 \| Maximum \| Development and Regulatory Approval Milestones
Business Acquisition [Line Items]
Contingent consideration							100,000,000
BlackThorn Merger Agreement \| NMRA-511 \| Maximum \| Sales-based Milestones
Business Acquisition [Line Items]
Contingent consideration							$ 100,000,000
BlackThorn Carveout Plan
Business Acquisition [Line Items]
Number of milestone achieved \| Milestones								0
Contingent consideration deemed due or payable								$ 0
Asset acquisition compensation recognized and paid										$ 1,800,000
Syllable Merger Agreement \| Syllable Life Sciences, Inc
Business Acquisition [Line Items]
Number of milestone achieved \| Milestones								0
Contingent consideration deemed due or payable								$ 0
Syllable Merger Agreement \| Syllable Life Sciences, Inc \| Maximum \| Development Milestones
Business Acquisition [Line Items]
Contingent consideration						$ 5,000,000
Alairion Merger Agreement \| Alairion, Inc
Business Acquisition [Line Items]
Number of milestone achieved \| Milestones								0
Alairion Merger Agreement \| Alairion, Inc \| Achievement of Specified Commercialization Events
Business Acquisition [Line Items]
Contingent consideration, milestone payment					$ 135,000,000
Alairion Merger Agreement \| Alairion, Inc \| Maximum \| Achievement of Specified Development Events
Business Acquisition [Line Items]
Contingent consideration, milestone payment					$ 33,500,000
Amgen Inc. Licenses \| Amgen Inc.
Business Acquisition [Line Items]
Number of milestone achieved \| Milestones								0
Contingent consideration deemed due or payable								$ 0
Amgen Inc. Licenses \| Amgen Inc. \| Series A-2
Business Acquisition [Line Items]
Upfront consideration transferred shares \| shares				20,000,000
Acquisition date fair value of shares transferred				$ 157,000,000
Amgen Inc. Licenses \| Amgen Inc. \| Maximum \| Case One
Business Acquisition [Line Items]
Contingent consideration payable in cash				360,000,000
Amgen Inc. Licenses \| Amgen Inc. \| Maximum \| Commercial Milestone Payment \| Case Two
Business Acquisition [Line Items]
Contingent consideration payable in cash				$ 360,000,000
Vanderbilt License
Business Acquisition [Line Items]
Contingent consideration, milestone payment settled in cash		$ 2,000,000
Number of milestone achieved \| Milestones								0
Acquired in-process research and development									$ 800,000
Vanderbilt License \| Maximum \| Achievement of Specified Development Events
Business Acquisition [Line Items]
Contingent consideration payable in cash			$ 42,400,000
Vanderbilt License \| Maximum \| Achievement of Specified Commercialization Events
Business Acquisition [Line Items]
Contingent consideration payable in cash			380,000,000
Vanderbilt License \| Vanderbilt IPR&D Assets
Business Acquisition [Line Items]
Upfront cash payment			$ 13,000,000